- Moderna shares closed up 6.98% at $194.82, a four-year high, after Chairman Noubar Afeyan met UAE Minister of State Saeed bin Mubarak Al Hajeri to explore cooperation in advanced pharmaceutical industries covering R&D, knowledge exchange, and UAE manufacturing capacity.
- The UAE talks are expected to strengthen Moderna's long-term financial stability, broaden its Middle East footprint, and diversify revenue streams.
- Investors are also focused on the updated readout from the Phase 3 INTerpath-001 trial of intismeran autogene plus Merck's Keytruda in melanoma; the trial previously met its primary recurrence-free survival endpoint and a key secondary target.
- Moderna is repositioning from a COVID-19 vaccine provider to a broad mRNA platform company spanning vaccines, oncology, rare diseases, and autoimmune therapies.
- The Phase 3 melanoma study for intismeran beat PD-1 monotherapy as an add-on and met both primary and secondary endpoints at interim analysis, and Moderna plans a biologics license application while preparing manufacturing and hospital support for commercialization.
- Moderna's pipeline includes expanding intismeran into lung, kidney, and bladder cancers, an off-the-shelf cancer prevention vaccine for Lynch syndrome, multiplexing T-cell engagers for multiple myeloma, and rare disease programs with pivotal PA data anticipated by year-end.
Quotes
“Moderna is transitioning from primarily a COVID-19 vaccine provider to a broad mRNA platform company, focusing on vaccines, oncology, rare diseases, and autoimmune therapies”
“The company's Phase 3 melanoma study for intismeran, developed with Merck, met primary and secondary endpoints, leading Moderna to plan a biologics license application”